Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Investors Crow For Shares Of Zoetis As It Begins Trading On The NYSE

This article was originally published in The Pink Sheet Daily

Executive Summary

Zoetis makes its debut on the public stock exchange, garnering the highest priced IPO since Facebook began trading last year.

Advertisement

Related Content

Valeant/Ackman Going Whole Hog On Zoetis As Plan B For Allergan?
Lilly Feeds The Beast, But Is Novartis Animal Health Unit Worth The Price?
Uptick In 4Q 2013 M&A Deal-Making Likely To Continue Into 2014, PwC Report Predicts
Novartis Seems Close to Consumer Health Sale – Analyst
Pfizer Reorganizes Internally As It Moves Closer To Decision On Splitting Business
Pfizer Reorganizes Internally As It Moves Closer To Decision On Splitting Business
Pfizer Moo’ved To Split Off Zoetis Business By July 2013
Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B
Reading Into Pfizer's Changes: First Steps For New CEO
Bristol Flying Solo As A Pure Biopharma After Mead Johnson Spin Out

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075245

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel